» Articles » PMID: 12846981

Mitochondria, Oxidative Damage, and Inflammation in Parkinson's Disease

Overview
Specialty Science
Date 2003 Jul 9
PMID 12846981
Citations 175
Authors
Affiliations
Soon will be listed here.
Abstract

The pathogenesis of Parkinson's disease (PD) remains obscure, but there is increasing evidence that impairment of mitochondrial function, oxidative damage, and inflammation are contributing factors. The present paper reviews the experimental and clinical evidence implicating these processes in PD. There is substantial evidence that there is a deficiency of complex I activity of the mitochondrial electron transport chain in PD. There is also evidence for increased numbers of activated microglia in both PD postmortem tissue as well as in animal models of PD. Impaired mitochondrial function and activated microglia may both contribute to oxidative damage in PD. A number of therapies targeting inflammation and mitochondrial dysfunction are efficacious in the MPTP model of PD. Of these, coenzyme Q(10) appears to be particularly promising based on the results of a recent phase 2 clinical trial in which it significantly slowed the progression of PD.

Citing Articles

Genetic mutations in kinases: a comprehensive review on marketed inhibitors and unexplored targets in Parkinson's disease.

Raza A, Raina J, Sahu S, Wadhwa P Neurol Sci. 2025; .

PMID: 39760821 DOI: 10.1007/s10072-024-07970-2.


1,4-dihydroxy-2-naphthoic acid prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced motor function deficits.

Madison C, Debler R, Gallegos P, Hillbrick L, Chapkin R, Safe S Behav Pharmacol. 2024; 36(1):40-46.

PMID: 39660867 PMC: 11781791. DOI: 10.1097/FBP.0000000000000806.


Diosgenin derivative ML5 attenuates MPTP-induced neuronal impairment via regulating AMPK/PGC-1α-mediated mitochondrial biogenesis and fusion/fission.

Fan J, Ding W, Liang Y, Wei Y, Huang Y, Ma L Am J Transl Res. 2024; 16(8):3582-3598.

PMID: 39262707 PMC: 11384354. DOI: 10.62347/JBRE5043.


Gene network analysis combined with preclinical studies to identify and elucidate the mechanism of action of novel irreversible Keap1 inhibitor for Parkinson's disease.

Arumugam M, Pachamuthu R, Rymbai E, Jha A, Rajagopal K, Kothandan R Mol Divers. 2024; .

PMID: 39145879 DOI: 10.1007/s11030-024-10965-y.


Effects of non-invasive vagus nerve stimulation on clinical symptoms and molecular biomarkers in Parkinson's disease.

Mondal B, Choudhury S, Banerjee R, Roy A, Chatterjee K, Basu P Front Aging Neurosci. 2024; 15:1331575.

PMID: 38384731 PMC: 10879328. DOI: 10.3389/fnagi.2023.1331575.